Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study

R Caporali, C Montecucco, O Epis, F Bobbio-Pallavicini, T Maio, M A Cimmino

Abstract

Objective—To evaluate in a prospective study whether patients with polymyalgia rheumatica (PMR) and patients with rheumatoid arthritis (RA) with PMR-like onset show distinctive clinical and laboratory features.

Methods—A cohort of 116 consecutive patients with bilateral girdle pain for at least one month and raised erythrocyte sedimentation rate (ESR) was studied and followed up for 12 months. Laboratory tests included determination of ESR, IgM rheumatoid factor, haemoglobin, white blood cell count, platelet count, percentage of CD8 lymphocytes, serum aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and glutamyltransferase concentrations.

Results—At first examination, RA was diagnosed in 22/116 (19%) patients and PMR in 94 (81%) patients. During the follow up period, 19 additional patients developed RA, and the diagnosis of PMR was confirmed in 65 (56%) patients at the end of the study. Of the clinical and laboratory features, only the presence of peripheral synovitis could differentiate patients who will develop RA from those with “true” PMR, but the positive predictive value of this feature was poor.

Conclusion—At present, there are no clinical or routine laboratory features allowing early differentiation between PMR and RA with PMR-like onset.

Patients and methods

We studied prospectively a cohort of 116 consecutive patients observed at our institutions. Inclusion criteria were: (a) age greater than 49 years; (b) bilateral girdle pain (with or without morning stiffness) for at least one month; (c) ESR > 40 mm at 1 hour (Westergren). Patients with a positive ANA test (> 1/160 on Hep2 cells) and/or raised serum creatine kinase concentrations were excluded from the study. Patients already treated with steroids or disease modifying anti-rheumatic drugs, with evidence of infectious diseases, neoplasms, or giant cell arteritis were also excluded.

Clinical assessment was performed by the same doctor at the first examination, monthly for the first six months, and every two months up to one year thereafter. In particular, systemic signs such as fever, weight loss, headache, and early morning stiffness were recorded. Peripheral synovitis and muscle atrophy were evaluated clinically. Laboratory tests were performed at the first visit and every two months. They included determination of ESR, IgM rheumatoid factor (RF), haemoglobin, white blood cell count, platelet count, percentage of CD8 lymphocytes (performed in 49 patients), serum aspartate aminotransferase,
alanine aminotransferase, alkaline phosphatase, and glutamyltransferase concentrations. RA was diagnosed according to the 1987 ACR (formerly ARA) criteria, and PMR was diagnosed as described by Jones and Hazleman. An x-ray examination of hands and wrists was performed at the first examination, after six months, and at the end of the study; clinical and laboratory criteria were checked at each examination. The study was discontinued after 12 months. After the first examination, patients not fulfilling the ACR criteria for RA were treated with prednisone alone at an initial dose of 17.5 mg/day. Prednisone was then tapered to maintain a dose of 5 mg/day after eight months. Patients with a diagnosis of RA were treated and followed according to standard clinical guidelines and were not considered for final evaluation.

STATISTICAL ANALYSIS

Differences between groups were evaluated using the non-parametric Mann-Whitney test for continuous variables and the \( \chi^2 \) test with continuity correction for categorical variables.

Table 1 Main clinical features in the two groups of patients, divided according to the final diagnosis

<table>
<thead>
<tr>
<th>Feature</th>
<th>PMR* (n=65)</th>
<th>RA* (n=19)</th>
<th>( p ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>20/45</td>
<td>7/12</td>
<td>NS*</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>70.1</td>
<td>68.8</td>
<td>NS</td>
</tr>
<tr>
<td>Fever</td>
<td>23</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>Weight loss</td>
<td>25</td>
<td>2</td>
<td>0.02</td>
</tr>
<tr>
<td>Morning stiffness &gt;1 hour</td>
<td>47</td>
<td>15</td>
<td>NS</td>
</tr>
<tr>
<td>Proximal muscular atrophy</td>
<td>1</td>
<td>3</td>
<td>0.03</td>
</tr>
<tr>
<td>Headache</td>
<td>15</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>Peripheral synovitis</td>
<td>17</td>
<td>15</td>
<td>0.0001†</td>
</tr>
</tbody>
</table>

PMR* = Polymyalgia rheumatica; RA* = rheumatoid arthritis; NS* = not significant. †p<0.002 after Bonferroni’s correction.

Table 2 Main radiological and laboratory features in the two groups of patients, divided according to the final diagnosis

<table>
<thead>
<tr>
<th>Feature</th>
<th>PMR* (n=65)</th>
<th>RA* (n=19)</th>
<th>( p ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erosions</td>
<td>0</td>
<td>0</td>
<td>NS*</td>
</tr>
<tr>
<td>ESR* (mm 1st hour) (mean)</td>
<td>74.9</td>
<td>83.6</td>
<td>NS</td>
</tr>
<tr>
<td>Rheumatoid factor (No of positive patients)</td>
<td>8</td>
<td>7</td>
<td>0.03</td>
</tr>
<tr>
<td>Rheumatoid factor (titre)</td>
<td>92 (32-424)</td>
<td>98 (40-820)</td>
<td>NS</td>
</tr>
<tr>
<td>Alkaline phosphatase and/or GT* increase</td>
<td>16</td>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>AST* and/or ALT* increase</td>
<td>2</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>WBC* &gt;10 x 10^9/l</td>
<td>15</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td>PLT* &gt;450 x 10^9/l</td>
<td>11</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>Haemoglobin &lt;105 g/l</td>
<td>10</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td>% CD8 (mean (SD))†</td>
<td>28 (7)</td>
<td>31 (9)</td>
<td>NS</td>
</tr>
</tbody>
</table>

PMR* = Polymyalgia rheumatica; RA* = rheumatoid arthritis; NS* = not significant; ESR* = erythrocyte sedimentation rate; GT* = glutamyltransferase; AST* = aspartate aminotransferase; ALT* = alanine aminotransferase; WBC* = white blood count; PLT* = platelet count. †Limited to 49 patients (39 PMR and 10 RA).

As multiple comparisons were performed, the Bonferroni adjustment was applied. The percentage of patients with persistent PMR or who developed RA during the follow up was calculated by the log rank test.

Results

DIAGNOSIS AND FOLLOW UP

At first examination, a diagnosis of RA was made in 22/116 (19%) patients, who were excluded from further study. An initial diagnosis of PMR was made in the remaining 94/116 (81%) patients who were followed up for 12 months. During this period, three patients developed a malignancy (gastric cancer, lung cancer, lymphoma), three developed clinical and histological signs of giant cell arteritis, and four were lost to follow up (fig 1). A total of 84 patients was therefore evaluable after 12 months. A good initial response to prednisone was seen in all these patients despite occasional flare ups of the symptoms or the involvement of additional joints in 25 patients. In 19 of these 25 patients, the diagnosis was changed to RA because the ACR criteria were now fulfilled. In the remaining six patients with flare ups, the diagnosis of PMR was confirmed. In this last group, an increase in prednisone dose up to the last previous dose led to a complete clinical and serological recovery. Therefore the final diagnosis was RA in 41 patients (22 at first examination and 19 during the follow up) and PMR in 65 patients. Figure 2 shows the curve of the patients maintaining their diagnosis of PMR over the follow up period and the time when the diagnosis of RA was made.

PRESENTING FEATURES

Patients with RA diagnosed at the first examination (22 patients) were not considered for the evaluation of presenting features. As depicted in fig 1, during the 12 months of follow up, 10 of 94 patients with an initial diagnosis of PMR were withdrawn from the study (four lost of to follow up and six for other diseases). Of the remaining 84 patients, 19 (23%) developed RA during the follow up, and 65 (77%) maintained the diagnosis of PMR.

These two groups were similar for age, sex, and inflammation indices (tables 1 and 2). Weight loss was more often observed in patients with a final diagnosis of PMR, whereas proximal muscle atrophy and peripheral synovitis were more common in patients with RA. However, after correction for multiple comparisons, only the presence of peripheral arthritis remained significantly different between the two groups. Arthritis was present in 17/65 (26%) patients with PMR and in 15/19 (79%) patients with RA (adjusted \( p<0.002 \)) (table 1). However, this clinical feature has a poor positive predictive value, as only 15 out of 32 (47%) patients with peripheral arthritis developed RA. Of the laboratory tests, only IgM RF positivity was more common in patients with RA than in patients with PMR, but this difference disappeared after Bonferroni’s correction; RF titre was also similar in the two groups of patients.
No significant differences were observed for the other laboratory variables including CD8 lymphocyte percentage, which was evaluated in a subset of 49 patients (39 PMR and 10 RA).

**Discussion**

Since Bagratuni’s first description of PMR, similarities between this condition and RA have been described. Several studies have shown that RA can be diagnosed in 6–17% of patients initially classified as PMR and followed up for three to five years. On the other hand, it is well known that a usually seronegative subset of elderly onset RA may show a PMR-like onset with prevalent involvement of the girdles, high ESR values, and good response to low dose steroid treatment. Moreover, inflammatory involvement of peripheral joints and/or tenosynovial structures is described in a high proportion of patients with PMR. The demonstration that PMR is a synovitis by arthroscopic biopsy and ultrasoundography of the shoulder joints may provide an explanation for such observations. However, the similarity and possible overlap in peripheral joints and/or tenosynovial structures is described in a high proportion of patients with PMR. The demonstration that PMR is a synovitis by arthroscopic biopsy and ultrasoundography of the shoulder joints may provide an explanation for such observations.

In our study we prospectively examined patients presenting with PMR-like onset. We noted that in 22 of these patients (19%), a diagnosis of RA was possible at the first examination, and in an additional 19 patients a diagnosis of RA was confirmed over a 12 month follow up. As a result, of 116 patients examined because of PMR-like symptoms at onset, 41 (35%) had RA or developed it within one year. The diagnosis of PMR was confirmed in 65 (56%) cases. In contrast, Bhulas and coworkers found RA subsequent to the diagnosis of PMR in only 17/149 patients (11%). This discrepancy may be due to the retrospective design of their study. In addition, these authors found cancer in four (2.6%) of their patients, a low frequency confirmed in our study (3/116; 2.6%).

Whether PMR and RA with a PMR-like onset are the same disease, or if some differences exist that could be helpful in the differential diagnosis is still a matter of debate. To investigate this topic further, we compared among patients satisfying at presentation the commonly used criteria for the diagnosis of PMR those with persistent PMR and those in whom RA developed during the follow up. The only significant difference between the two groups was the more common involvement of peripheral joints in patients with RA. However, this difference seems to be of poor clinical value, because peripheral arthritis was present in 15/19 (79%) patients with RA but also in 17/65 (26%) patients with PMR. The last figure is very similar to that recently reported by Salvarani and coworkers for 177 Italian patients with PMR and Gran and Myklebust in a prospective study from Southern Norway. As a result, less than half of the patients with girdle involvement and peripheral synovitis can be expected to develop RA after an initial diagnosis of PMR. The importance of a low percentage of CD8 T lymphocyte before treatment in distinguishing PMR and RA at disease onset has been reported by Corrigal and coworkers. Our data also showed a lower CD8 cell count in patients with PMR in comparison with patients with RA. The usefulness of this test for differential diagnosis cannot be confirmed because the values obtained in the two groups of patients were largely overlapping. geographical differences may partially account for this difference because our data are very similar to those reported by Boiardi and coworkers for patients with PMR and RA from another location in Northern Italy.

As expected, RF positivity was more common in patients with RA than in patients with PMR. However, this difference was not statistically significant. The high prevalence of RF positivity in our patients with either PMR or RA with PMR-like onset, usually described as seronegative diseases in other series, is surprising. Epidemiological studies on RF prevalence in the Italian population are lacking. However, environmental and/or genetic factors leading to a high rate of RF positivity in the Italian population exist. For example, hepatitis C virus infection, with or without mixed cryoglobulinaemia, is a potent inducer of RF production by plasma cells. The prevalence of antibodies to hepatitis C virus in the Italian general population is between 3.2% and 12.6%, and can reach 40% among elderly subjects of certain Italian regions.

The evaluation of new diagnostic tools such as antibodies against putatively citrullinated antigens (SA filagrin, CCP) could be of interest in this subset of patients, even though their predictive value in seronegative RA appears to be low; studies on this topic are warranted.

Several other clinical and laboratory variables have been suggested as useful in the differential diagnosis between PMR and RA with PMR-like onset. These include scintigraphic evaluation of the shoulder, thrombocytosis, serum cytidine deaminase, and antibodies to laminin B2 protein. However, all these observations need further confirmation and none of them is usually used in clinical practice.

On the other hand, HLA typing does not seem to allow early differentiation between RA and PMR.

We are aware that a one year study does not allow us to draw definite conclusions. Notwithstanding, the data from this prospective study appear of some interest, in that about 35% of patients presenting with symptoms resembling PMR actually have or will develop RA during 12 months of follow up. More interestingly, when considering only patients with an initial diagnosis of PMR, more than 20% will develop overt RA during the follow up. At present, there are no clinical or routine laboratory features allowing early differentiation between these patients and patients with persisting PMR.


www.annrheumdis.com
Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study
R Caporali, C Montecucco, O Epis, F Bobbio-Pallavicini, T Maio and M A Cimmino

Ann Rheum Dis 2001 60: 1021-1024
doi: 10.1136/ard.60.11.1021

Updated information and services can be found at:
http://ard.bmj.com/content/60/11/1021

These include:
References
This article cites 31 articles, 9 of which you can access for free at:
http://ard.bmj.com/content/60/11/1021#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Connective tissue disease (4253)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Pain (neurology) (883)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/